Evidence map›Paper›PMID 34716967›Full record

ArticleCancer science2022

Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia.

Takashi Mikami, Itaru Kato, James Badger Wing, Hiroo Ueno, Keiji Tasaka, Kuniaki Tanaka, Hirohito Kubota, Satoshi Saida, Katsutsugu Umeda, Hidefumi Hiramatsu and 15 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 2 countries.

Takashi MikamiDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0003-1846-4500
Itaru KatoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-2932-4960
James Badger WingLaboratory of Human Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Hiroo UenoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keiji TasakaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-2708-3876
Kuniaki TanakaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hirohito KubotaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoshi SaidaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Katsutsugu UmedaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-6844-2011
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomoya IsobeDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuteru HiwatariDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ai OkadaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Kenichi ChibaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Hiroko TanakaM&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
Satoru MiyanoM&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
Yuki ArakawaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Koichi OshimaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Souichi AdachiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keiko IwaisakoDepartment of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shimon SakaguchiLaboratory of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPSaitama Children's Medical Center · JPThe University of Tokyo · JPTokyo Medical and Dental University · JPDoshisha University · JPOsaka University of Human Sciences · JPThe University of Osaka · JP

Funding

AMED JP21ck0106531Bristol Myers SquibbMochida Memorial Foundation for Medical and Pharmaceutical ResearchMother and Child Health Foundation
6 · The paper itself

Abstract

Due to the considerable success of cancer immunotherapy for leukemia, the tumor immune environment has become a focus of intense research; however, there are few reports on the dynamics of the tumor immune environment in leukemia. Here, we analyzed the tumor immune environment in pediatric B cell precursor acute lymphoblastic leukemia by analyzing serial bone marrow samples from nine patients with primary and recurrent disease by mass cytometry using 39 immunophenotype markers, and transcriptome analysis. High-dimensional single-cell mass cytometry analysis elucidated a dynamic shift of T cells from naïve to effector subsets, and clarified that, during relapse, the tumor immune environment comprised a T helper 1-polarized immune profile, together with an increased number of effector regulatory T cells. These results were confirmed in a validation cohort using conventional flow cytometry. Furthermore, RNA transcriptome analysis identified the upregulation of immune-related pathways in B cell precursor acute lymphoblastic leukemia cells during relapse, suggesting interaction with the surrounding environment. In conclusion, a tumor immune environment characterized by a T helper 1-polarized immune profile, with an increased number of effector regulatory T cells, could contribute to the pathophysiology of recurrent B cell precursor acute lymphoblastic leukemia. This information could contribute to the development of effective immunotherapeutic approaches against B cell precursor acute lymphoblastic leukemia relapse.

Indexed as

AdolescentBiomarkers, TumorBone MarrowChildChild, PreschoolFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInfantMaleNeoplasm Recurrence, LocalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequence Analysis, RNASingle-Cell AnalysisBiomarkers, TumorB cell leukemiaimmune responseregulatory T cellrelapseTh1

Identifiers

PMID34716967
PMCPMC8748249
OpenAlexW3209994121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.